ND-630 (Firsocostat) (Synonyms: Firsocostat, GS-0976) |
Catalog No.GC19261
One-Click Copy Product Info
|
ND-630 (Firsocostat) is an acetyl-CoA carboxylase (ACC) inhibitor that suppresses the activity of ACC1 (IC50=2.1nM) and ACC2 (IC50=6.1nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1434635-54-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ND-630 (Firsocostat) is an acetyl-CoA carboxylase (ACC) inhibitor that suppresses the activity of ACC1 (IC50=2.1nM) and ACC2 (IC50=6.1nM)[1-2]. ND-630 can inhibit fatty acid synthesis, improve insulin sensitivity, and exert beneficial effects on dyslipidemia[3-4].
In vitro, treatment of prostate cancer cells (PC-3, DU145) with ND-630 (5nM) significantly inhibits cell proliferation, migration, and invasion, while reducing fatty acid and triglyceride synthesis[5]. Pretreatment of mouse primary chondrocytes with ND-630 (5nM), followed by culture under high glucose (20mM) and high insulin (20nM) conditions for 7–10 days, significantly inhibits acetyl-CoA carboxylase (ACC) activity, lowers malonyl-CoA levels, and reduces intracellular lipid accumulation[6].
In vivo, oral administration of ND-630 (5mg/kg; twice daily) to Zucker diabetic fatty (ZDF) rats for 37 days significantly reduces hepatic steatosis, improves insulin sensitivity, decreases weight gain without affecting food intake, and has beneficial effects on dyslipidemia[7]. Oral administration of ND-630 (4–16mg/kg/day) to adenine diet-induced chronic kidney disease (CKD) C57BL/6 mice for 4 weeks significantly lowers serum creatinine and blood urea nitrogen levels, alleviates renal tubular injury and collagen deposition, and mitigates oxidative stress and inflammatory responses[8].
References:
[1] Alkhouri N, Lawitz E, Noureddin M, et al. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020 Feb;29(2):135-141.
[2] Kwon Y, Gottmann P, Wang S, et al. Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025 Jan;82(1):18-27.
[3] Younis IR, Nelson C, Weber EJ, et al. Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment. J Clin Pharmacol. 2024 Jul;64(7):878-886.
[4] Lawitz EJ, Bhandari BR, Ruane PJ, et al. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol. 2023 Jan;21(1):143-152.e3.
[5] Wu YP, Zheng WC, Huang Q, et al. ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. J Transl Med. 2023 Dec 4;21(1):877.
[6] Liu H, Witzigreuter L, Sathiaseelan R, et al. Obesity promotes lipid accumulation in mouse cartilage-A potential role of acetyl-CoA carboxylase (ACC) mediated chondrocyte de novo lipogenesis. J Orthop Res. 2022 Dec;40(12):2771-2779.
[7] Harriman G, Greenwood J, Bhat S, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1796-805.
[8] Liu X, Peng Y, Wu S, et al. ND-630, an acetyl-CoA carboxylase inhibitor, prevents renal fibrosis in adenine-induced CKD mice. Naunyn Schmiedebergs Arch Pharmacol. 2025 Sep 3.
| Cell experiment [1]: | |
Cell lines | Prostate cancer cell lines (PC-3, DU145) |
Preparation Method | Prostate cancer cells were maintained in their respective media (F-12K for PC-3, MEM for DU145) supplemented with 10% fetal bovine serum (FBS). Cells were treated with the acetyl-CoA carboxylase (ACC) inhibitor ND-630 at concentrations of 5nM for 48 hours. |
Reaction Conditions | 5nM; 48 hours |
Applications | ND-630 attenuated the enhanced cell proliferation, migration, and invasion induced by circKIF18B_003 overexpression. ND-630 also decreased the expression of fibrosis markers (α-SMA and vimentin) and reduced glucose incorporation into de novo fatty acid synthesis. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Mice were divided into four groups: control, CKD, CKD+ND-630 low-dose (4mg/kg/d), and CKD+ND-630 high-dose (16mg/kg/d). Chronic kidney disease (CKD) was induced by feeding a 0.2% adenine diet for 4 weeks. ND-630 treatment was administered concurrently with CKD induction via oral gavage. |
Dosage form | 4mg/kg/d and 16mg/kg/d; oral gavage; Daily administration for 4 weeks. |
Applications | ND-630 significantly decreased serum creatinine (Scr) and blood urea nitrogen (BUN) levels in adenine-induced CKD mice, with greater efficacy at higher doses. Administration of ND-630 limited renal tubular injury and collagen deposition, suppressed the expression of fibrosis markers (α-smooth muscle actin and vimentin), inhibited ACC1 expression and malonyl-CoA production, and reduced lipid accumulation in the kidneys. Additionally, ND-630 protected against oxidative stress, decreased inflammatory cytokine levels (TNF-α and IL-6), and antagonized TGF-β1/Smad signaling activation in CKD kidneys. |
References: | |
| Cas No. | 1434635-54-7 | SDF | |
| Synonyms | Firsocostat, GS-0976 | ||
| Canonical SMILES | O=C(C(C(C)=C(C1=NC=CO1)S2)=C2N3C[C@H](OC4CCOCC4)C5=C(OC)C=CC=C5)N(C(C)(C)C(O)=O)C3=O | ||
| Formula | C28H31N3O8S | M.Wt | 569.63 |
| Solubility | DMSO : ≥ 50 mg/mL (87.78 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7555 mL | 8.7776 mL | 17.5553 mL |
| 5 mM | 351.1 μL | 1.7555 mL | 3.5111 mL |
| 10 mM | 175.6 μL | 877.8 μL | 1.7555 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)